JP2025517672A5 - - Google Patents

Info

Publication number
JP2025517672A5
JP2025517672A5 JP2024566410A JP2024566410A JP2025517672A5 JP 2025517672 A5 JP2025517672 A5 JP 2025517672A5 JP 2024566410 A JP2024566410 A JP 2024566410A JP 2024566410 A JP2024566410 A JP 2024566410A JP 2025517672 A5 JP2025517672 A5 JP 2025517672A5
Authority
JP
Japan
Prior art keywords
compound according
chemical formula
group
formula
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024566410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/062208 external-priority patent/WO2023217744A1/en
Publication of JP2025517672A publication Critical patent/JP2025517672A/ja
Publication of JP2025517672A5 publication Critical patent/JP2025517672A5/ja
Withdrawn legal-status Critical Current

Links

JP2024566410A 2022-05-10 2023-05-09 プロドラッグおよびその使用 Withdrawn JP2025517672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22172545 2022-05-10
EP22172545.0 2022-05-10
PCT/EP2023/062208 WO2023217744A1 (en) 2022-05-10 2023-05-09 Prodrugs of glp-1 polypeptide and uses thereof

Publications (2)

Publication Number Publication Date
JP2025517672A JP2025517672A (ja) 2025-06-10
JP2025517672A5 true JP2025517672A5 (cg-RX-API-DMAC7.html) 2026-05-01

Family

ID=81940650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566410A Withdrawn JP2025517672A (ja) 2022-05-10 2023-05-09 プロドラッグおよびその使用

Country Status (7)

Country Link
US (1) US20250304645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522220A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517672A (cg-RX-API-DMAC7.html)
CN (1) CN119173275A (cg-RX-API-DMAC7.html)
AR (1) AR129270A1 (cg-RX-API-DMAC7.html)
TW (1) TW202346324A (cg-RX-API-DMAC7.html)
WO (1) WO2023217744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120659805A (zh) * 2023-10-31 2025-09-16 深圳信立泰药业股份有限公司 Glp-1化合物及其制备方法与应用
WO2026052063A1 (en) * 2024-09-06 2026-03-12 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Glp-1 polypeptide prodrugs and uses thereof
WO2026139053A1 (zh) * 2024-12-27 2026-07-02 深圳信立泰药业股份有限公司 一种包含glp-1化合物的药物组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
ES2810153T3 (es) 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Similar Documents

Publication Publication Date Title
AU2008365555B2 (en) Glucagon analogues
US8680049B2 (en) Glucagon analogues
AU2021361263A1 (en) GLP-1/GIP dual agonists
JP2025161829A (ja) インスリン誘導体
JP2023526973A5 (cg-RX-API-DMAC7.html)
JP2023071869A (ja) グルカゴンおよびglp-1受容体の長時間作用型コアゴニスト
US20070244041A1 (en) Peptide Yy Analogues
AU2012357739A1 (en) Glucagon analogues
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
JP2013530969A (ja) グルカゴン類似体
JP2013517307A5 (cg-RX-API-DMAC7.html)
JP2023545684A5 (cg-RX-API-DMAC7.html)
JP2010174016A (ja) Glp−1類似体
JP2025525218A (ja) インクレチンアナログおよびその使用
JP2023502005A5 (cg-RX-API-DMAC7.html)
JP2025172864A5 (cg-RX-API-DMAC7.html)
WO2024175930A1 (en) Compounds
JP2023533413A (ja) 長時間作用型glp-1およびグルカゴン受容体デュアルアゴニスト
JP2025542352A (ja) Glp1/gip/npy2受容体トリプルアゴニスト
CN118843640A (zh) 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途
WO2020249966A1 (en) Novel peptide hormone analogues
JP2021505656A (ja) グルカゴン様ペプチド
WO2022177018A1 (ja) 長時間作用型アドレノメデュリン誘導体の製造方法
JP2023538871A (ja) エキセンジン-4ペプチド類似体
WO2026067799A1 (zh) Glp-1受体和胰淀素受体的共激动剂